ERBB2 and breast carcinoma: The comparison to HER2 IQFISH pharmDx was performed on 422 breast cancer specimens and here, the results for NPA and PPA were 98.2% (95% CI, 95.4-99.3) and 93.1% (95% CI, 87.0-96.5), respectively (58).